Authors:
SR Hingorani, DA Tuveson
Journal name: 
Cancer Cell
Citation info: 
3(5):414-417
Abstract: 
Our expanding experience with imatinib mesylate provides instructive lessons on the power and pitfalls of targeted therapy. The often impressive initial clinical responses seen with imatinib in a variety of malignancies inevitably give way to the emergence of resistant disease. Recent findings reveal several mechanisms of resistance and suggest ways to overcome them.
DOI: 
http://doi.org/10.1016/s1535-6108(03)00115-6
E-pub date: 
01 May 2003
Users with this publication listed: 
David Tuveson